​

MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

ForecastOwnershipFinancialsChart

Previous Close

$39.15

52W Range

$31.42 - $58.26

50D Avg

$38.97

200D Avg

$46.27

Market Cap

$2.55B

Avg Vol (3M)

$420.40K

Beta

1.31

Div Yield

-

MLTX Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

100

IPO Date

Oct 20, 2020

Website

MLTX Performance

MLTX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-54.12M$-65.06M
Net Income$-120.68B$-36.01M$-64.51M
EBITDA-$-54.11M$-65.05M
Basic EPS$-1.92K$-0.73$-2.20
Diluted EPS$-1.92K$-0.73$-2.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
ELVNEnliven Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
CMPXCompass Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
ACLXArcellx, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PLRXPliant Therapeutics, Inc.
TVTXTravere Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
GPCRStructure Therapeutics Inc.
NUVLNuvalent, Inc.
AKROAkero Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ETNB89bio, Inc.
ABOSAcumen Pharmaceuticals, Inc.